October 5, 2022
Press Releases for Artiva Biotherapeutics
September 20, 2022
Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors
June 13, 2022
Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities
June 6, 2022
Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer
May 5, 2022
Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board
April 11, 2022
Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers
March 21, 2022
Artiva Biotherapeutics Appoints Laura Bessen, M.D., to Its Board of Directors
January 4, 2022
Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer
September 30, 2021
Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement
August 12, 2021